Cancer vaccines

Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19

Friday, September 18, 2020 - 12:32am

Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.

Key Points: 
  • Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.
  • In a publication submitted Monday, September 14 (now available on the bioRxiv preprint server ), the authors present a systematic study on rational vaccine design and evaluation of vaccine response in mice.
  • In particular, Zhu and his team propose a new spike antigen design (S2GHR2) and displayed it on several SApNPs as COVID-19 vaccine candidates.
  • In practice, we have seen similar performance from the Merck HPV Gardasil vaccine which is essentially a protein nanoparticle vaccine.

Baum Hedlund Files Gardasil Lawsuit Against Merck on Behalf of Man

Thursday, September 17, 2020 - 12:56am

ORANGE COUNTY, Calif., Sept. 16, 2020 /PRNewswire/ -- Baum Hedlund Aristei & Goldman filed aGardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine.

Key Points: 
  • ORANGE COUNTY, Calif., Sept. 16, 2020 /PRNewswire/ -- Baum Hedlund Aristei & Goldman filed aGardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine.
  • But Merck knew that Gardasil was neither safe nor effective at preventing cervical cancer, and worse, the company knew that Gardasil could cause a host of serious health issues."
  • Baum Hedlund Aristei & Goldmanis one of the nation's leading law firms representing victims who have sustained injuries after receiving the Gardasil HPV vaccine .
  • Since 1973, Baum Hedlund Aristei & Goldman has won over $4 billion in settlements and verdicts on behalf of clients across all areas of practice.

Worldwide Cancer Vaccines Industry to 2027 - Featuring Advaxis, Amgen & Dynavax Technologies Among Others

Tuesday, September 8, 2020 - 4:45pm

Cancer vaccines are popularly used to treat various types of cancers such as breast cancer, lung cancer, prostate cancer, and cervical cancer.

Key Points: 
  • Cancer vaccines are popularly used to treat various types of cancers such as breast cancer, lung cancer, prostate cancer, and cervical cancer.
  • Preventive cancer vaccines are traditional cancer vaccines used in healthy people to prevent cancer.
  • In addition, increase in cancer vaccines usage combined with other therapies, surge in demand for cancer vaccines, the rise in public awareness toward benefits of cancer vaccines, increase in prevalence of human papilloma virus (HPV) infections, and launch of new cancer vaccines further fuel market growth.
  • By technology, the market is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines.

Global Cancer Vaccines Market (2020 to 2027) - by Technology, Type, Indication and End-user - ResearchAndMarkets.com

Thursday, September 3, 2020 - 5:20pm

Cancer vaccines are popularly used to treat various types of cancers such as breast cancer, lung cancer, prostate cancer, and cervical cancer.

Key Points: 
  • Cancer vaccines are popularly used to treat various types of cancers such as breast cancer, lung cancer, prostate cancer, and cervical cancer.
  • There are two types of vaccines available in market, namely, preventive cancer vaccines and therapeutic cancer vaccines.
  • In addition, increase in cancer vaccines usage combined with other therapies, surge in demand for cancer vaccines, the rise in public awareness toward benefits of cancer vaccines, increase in prevalence of human papilloma virus (HPV) infections, and launch of new cancer vaccines further fuel market growth.
  • By technology, the market is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines.

Americans are not optimistic that a vaccine for the COVID-19 virus will be available to the public before the end of the year

Wednesday, September 2, 2020 - 4:00pm

Only one-third of Americans are optimistic that a vaccine will be available before year-end.

Key Points: 
  • Only one-third of Americans are optimistic that a vaccine will be available before year-end.
  • Some differences in opinion are evident by age, with those 55 or older being least optimistic.
  • Meanwhile, men are notably more optimistic than women, as are higher income earners and those with higher education.
  • Regardless of when the vaccine is available, Americans were asked how likely they are to personally get the vaccination once it is available.

VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020

Monday, August 31, 2020 - 1:00pm

Looking back at the data from the CONSTANT study, its clear that the immunogenicity of the tri-antigenic vaccine, Sci-B-Vac, is significantly higher than that of the mono-antigenic vaccine, Engerix-B, said Dr. Finn.

Key Points: 
  • Looking back at the data from the CONSTANT study, its clear that the immunogenicity of the tri-antigenic vaccine, Sci-B-Vac, is significantly higher than that of the mono-antigenic vaccine, Engerix-B, said Dr. Finn.
  • This data implies that Sci-B-Vac may be an improved alternative for adult vaccination against Hepatitis B.
  • VBI Vaccines Inc. ( Nasdaq: VBIV ) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.
  • VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Cancer Vaccines Market to Reach $7.30 Bn, Globally, by 2027 at 12.6% CAGR, Allied Market Research

Monday, August 17, 2020 - 2:15pm

PORTLAND, Ore., Aug. 17, 2020 /PRNewswire/ -- Allied Market Research published a report, titled, " Cancer Vaccines Market by Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, and Viral Vector & DNA Cancer Vaccines), Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Indication (Cervical Cancer, Prostate Cancer, and Others), and End User (Pediatrics and Adults): Global Opportunity Analysis and Industry Forecast, 20202027."

Key Points: 
  • PORTLAND, Ore., Aug. 17, 2020 /PRNewswire/ -- Allied Market Research published a report, titled, " Cancer Vaccines Market by Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, and Viral Vector & DNA Cancer Vaccines), Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Indication (Cervical Cancer, Prostate Cancer, and Others), and End User (Pediatrics and Adults): Global Opportunity Analysis and Industry Forecast, 20202027."
  • Download Sample Report with Detailed COVID-19 Impact Analysis at: https://www.alliedmarketresearch.com/request-for-customization/1453?reqf...
    Rise in prevalence of human papilloma virus (HPV) cancer, increase in administration of prophylactic cancer vaccines, surge in development of new cancer vaccines, and launch and approval of new cancer vaccines propel the global cancer vaccines market.
  • Based on technology, the recombinant cancer vaccines segment held the largest share in 2019, contributing to more than four-fifths of the global cancer vaccines market.
  • Based on type, the preventative cancer vaccines segment dominated the global cancer vaccines market in 2019, contributing to 89% of the market.

Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago’s COVID-19 Vaccine Candidate with Dynavax’s CpG 1018 Adjuvant

Tuesday, July 14, 2020 - 1:00pm

The previously announced collaboration is evaluating the combination of Medicagos Coronavirus Virus-Like Particle (CoVLP) with Dynavaxs CpG 1018, the adjuvant contained in Dynavaxs U.S. FDA-approved adult hepatitis B vaccine.

Key Points: 
  • The previously announced collaboration is evaluating the combination of Medicagos Coronavirus Virus-Like Particle (CoVLP) with Dynavaxs CpG 1018, the adjuvant contained in Dynavaxs U.S. FDA-approved adult hepatitis B vaccine.
  • Combining Medicagos technology with Dynavaxs CpG 1018 adjuvant, the companies expect to be able to deliver up to 100 million doses by the end of 2021.
  • CpG 1018 is the adjuvant used in HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration (FDA).
  • Dynavax is also further developing CpG 1018 as an advanced vaccine adjuvant through research collaborations and partnerships.

Worldwide Human Papillomavirus (HPV) Vaccines Overview 2020 - Pipeline & Marketed Vaccines, Regulatory Events, Clinical Trial Landscape, Future Trends, KOL Insights, Unmet Needs, Sales (2015-2024)

Thursday, June 18, 2020 - 9:30pm

DUBLIN, June 18, 2020 /PRNewswire/ -- The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 18, 2020 /PRNewswire/ -- The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade.
  • Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs).
  • In 2014, Gardasil 9, a nine-valent vaccine capable of protecting from an additional 20% of HPV-related cancers, superseded Gardasil.

Interdisciplinary Consortium Receives Grant to Develop Next-Generation Cell-Based Cancer Vaccines

Wednesday, June 17, 2020 - 3:00pm

Saint-Gobain Life Sciences, Kanyr Pharma Inc., the RI-MUHC and McGill University have formed a new interdisciplinary consortium to make this technology more accessible.

Key Points: 
  • Saint-Gobain Life Sciences, Kanyr Pharma Inc., the RI-MUHC and McGill University have formed a new interdisciplinary consortium to make this technology more accessible.
  • In this project, dendritic cell cancer vaccines will be generated in Saint-Gobains VueLife C Series FEP bags.
  • View the full release here: https://www.businesswire.com/news/home/20200617005121/en/
    Interdisciplinary partnership between Saint-Gobain, Kanyr Pharma, and McGill in the development of optimized culture environments for dendritic cell cancer vaccines.
  • The ImmunyrTM technology was developed by Kanyr Pharma to activate each patients own immune system to target several types of cancer.